Progression while Receiving Preoperative Chemotherapy Should Not Be an Absolute Contraindication to Liver Resection for Colorectal Metastases

L Vigano, L Capussotti, E (Eduardo) Barroso, G Nuzzo, C Laurent, J.N.M. IJzermans, JF Gigot, J Figueras, T Gruenberger, DF Mirza, D Elias, G Poston, C Letoublon, H Isoniemi, J Herrera, FC Sousa, F Pardo, V Lucidi, I Popescu, R Adam

Research output: Contribution to journalArticleAcademicpeer-review

71 Citations (Scopus)


Tumor progression while receiving neoadjuvant chemotherapy (PD) has been associated with poor outcome and is commonly considered a contraindication to liver resection (LR). This study aims to clarify in a large multicenter setting whether PD is always a contraindication to LR. Data from the LiverMetSurvey international registry were analyzed. Patients undergoing LR for colorectal metastases without extrahepatic disease after neoadjuvant chemotherapy between 1990 and 2009 were reviewed. Among 2143 patients, PD occurred in 176 (8.2 %). Risk of progression was increased after 5-FU or irinotecan (22.7 % vs. 6.8 % after other regimens, p < 0.0001; 14.9 % vs. 7.2 %, p < 0.0001), while it was reduced after oxaliplatin (5.6 % vs. 12.0 %, p < 0.0001) and still diminished among patients receiving targeted therapies (2.6 %). PD was an independent prognostic factor of survival at multivariate analysis (35 % vs. 49 %, p = 0.0006). In the PD group, 3 independent prognostic factors were iden PD is a negative prognostic factor, but it is not an absolute contraindication to LR. Patients with PD could be scheduled for LR except for those with > 3 metastases and a parts per thousand yen50 mm, or CEA a parts per thousand yen200 ng/mL in whom further chemotherapy is recommended.
Original languageUndefined/Unknown
Pages (from-to)2786-2796
Number of pages11
JournalAnnals of Surgical Oncology
Issue number9
Publication statusPublished - 2012

Research programs

  • EMC MM-03-47-11

Cite this